Tag: Conjugate
Women with Highest Expression of Target Protein Benefited Most of Experimental...
The antibody-drug conjugate DMUC5754A, a novel trial drug of a relatively new class of agents developed by Genentech, a member of the Roche Group,...
Second Generation HER2-antibody-drug conjugate Offers Best-in-Class Potential and Improved Therapeutic Index
In pre-clinical xenograft studies using patient-derived breast cancer and non-small-cell lung cancer material, Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported...
Antibody-drug Conjugate for MBC Highlights Importance of Personalised Approach to Cancer...
Results of the first randomized phase II study, known as TDM4450g, in patients with previously untreated HER2-positive metastatic breast cancer (mBC) were presented today at...
Phase I Trial of Loaded Antibody Establishes Dose, Catalogues Side Effects...
An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38% of patients with relapsed or therapy-resistant Hodgkin lymphoma enrolled in...
